CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, ...
Yahoo Finance

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous ...

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
The Bay State Banner

Composting cooperative CERO wants to ensure sustainability for its workers as well as the environment

But CERO’s mission goes a step further than environmental sustainability. And as a worker-owned cooperative, CERO helps ensure that its employees have safe jobs, a good working environment and decent ...
Benzinga.com

Why CERo Therapeutics Stock Is Soaring

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares are racing higher Thursday after the company announced the publication of preclinical research on the use of its clinical candidate CER-1236 to ...
Hosted on MSN

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating ...
Business Wire

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell ...

SOUTH SAN FRANCISCO & OAKLAND, Calif.--(BUSINESS WIRE)--CERo Therapeutics, Inc. (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics ...
Hosted on MSN

Cero announces third dose for patients in Phase 1 trial of CER-1236

CERo Therapeutics (CERO) announced that investigators have been authorized under the study protocol to administer a third infusion of CER-1236 to a patient enrolled in the first cohort of its ongoing ...